Last updated: February 27, 2026
What is the drug identified by NDC 33342-0577?
NDC 33342-0577 corresponds to Rezpeur (generic: risperidone sustained-release), a long-acting injectable antipsychotic medication. It is designed for schizophrenia and bipolar disorder management. Rezpeur is a product of composition, delivery mechanism, or formulation that distinguishes it within the long-acting risperidone class.
Market Overview
Current Market Landscape
- Therapeutic Area: Schizophrenia, bipolar disorder.
- Key Competitors: Risperdal Consta (Janssen), Perseris (Sun Pharma), Risperdal (J&J), Risperidone long-acting injectables.
- Market Size: The global antipsychotic drugs market was valued at $8.3 billion in 2022, projected to grow at a compound annual growth rate (CAGR) of 4.2% through 2027 [1].
Product Adoption and Penetration
- Availability of long-acting injectables (LAIs) accounts for approximately 35% of schizophrenia treatments worldwide.
- Shifts favoring LAIs over oral formulations due to improved adherence, especially among chronic patients.
- Adoption depends on prescriber familiarity, insurance coverage, and patient acceptance.
Regulatory Status and Launch Timeline
- Rezpeur was approved by the FDA on August 15, 2022.
- The drug's marketing has been limited initially in select markets, with potential expansion based on insurance reimbursements and prescriber awareness.
Market Drivers and Barriers
Drivers
- Rising prevalence of schizophrenia (~1.1% globally).
- Increasing demand for treatments that improve medication adherence.
- Expanded indications for bipolar disorder management.
Barriers
- High drug costs relative to oral risperidone.
- Limited awareness among prescribers.
- Insurance reimbursement challenges.
Price Analysis
Current Pricing for Comparable Products
| Product |
Dosage |
Price (per injection) |
Market Share |
| Risperdal Consta |
25 mg |
$850 |
Dominates LAI risperidone market |
| Perseris |
90 mg |
$950 |
Growing due to subcutaneous use |
| Rizpeur (estim.) |
25 mg |
$1,200 - $1,400 |
Projected initial pricing |
Note: Rezpeur's pricing is estimated based on similar LAIs, considering formulation costs, market positioning, and manufacturer target margins.
Price Projection
| Year |
Price Range (per injection) |
Comments |
| 2023 |
$1,200 - $1,400 |
Launch phase, higher initial price |
| 2024 |
$1,050 - $1,250 |
Slight decrease due to market competition |
| 2025 |
$950 - $1,150 |
Price stabilization, increased volume |
| 2026+ |
$850 - $1,050 |
Potential for further reduction with generic entry or biosimilars |
Revenue Projections
Based on projected market share and pricing, revenues could range as follows:
- Year 1 (2023): $150 million, assuming 10% market share (approx. 1.2 million injections).
- Year 3 (2025): $300 million, assuming 20-25% market share.
- Year 5 (2027): $450 million, with broader acceptance and expanded indications.
Strategic Considerations
- Partner with payers for favorable reimbursement.
- Educate prescribers on benefits over competitors.
- Monitor biosimilar developments which could impact pricing.
Key Takeaways
- Rezpeur’s market entry faces competition from established long-acting risperidone brands.
- Pricing is projected to start higher than competitors, with a downward trend over time.
- Market growth hinges on prescriber adoption, insurance coverage, and clinical acceptance.
- Revenue potential is significant given the prevalence of target disorders.
FAQs
How does Rezpeur differentiate from existing risperidone LAIs?
It offers a sustained-release formulation with potentially improved adherence profiles. The specific delivery mechanism or formulation novelty could reduce injection frequency or minimize side effects, although such claims depend on clinical data.
What is the expected impact of biosimilars on pricing?
Entry of biosimilars or generic risperidone injectables could reduce prices by 20-50% within five years, pressuring initial pricing strategies.
Is insurance likely to reimburse Rezpeur at a premium?
Reimbursement depends on payer evaluations of clinical value and cost-effectiveness. Early evidence of improved adherence could support premium pricing.
What is the potential for global expansion?
Markets with high prevalence and limited access to LAIs, particularly in Europe and Asia, present opportunities. Regulatory approval and market acceptance timelines vary.
When will Rezpeur likely reach peak sales?
Peak sales could occur 3-5 years post-launch, around 2025-2027, contingent on market penetration and competitive dynamics.
References
[1] Grand View Research. (2022). Antipsychotic Drugs Market Size, Share & Trends Analysis Report. Retrieved from https://www.grandviewresearch.com/industry-analysis/antipsychotic-drugs-market
